Glatiramer acetate

Copaxone - API Insight, 2019-2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2019
Health, Pharmaceutical, Glatiramer acetate, Application programming interface

The "Copaxone - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Copaxone - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Copaxone - API Insight, 2019 provides product and API manufacturers' details across the globe along with the location.
  • The report gives the clear idea on the country wise DMF filed by worldwide companies related to Copaxone.
  • The report also highlights the patent details of Copaxone.

Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

Retrieved on: 
Monday, April 1, 2019
Health, Pharmaceutical, Other Health, General Health, Drugs, Glatiramer acetate, Teva Pharmaceutical Industries, Companies, Economy of Israel, Teva, European Patent Office, Tel Aviv Stock Exchange

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Offices (EPO) Opposition Division upheld patent EP 2 949 335 covering Tevas COPAXONE 40mg product in Europe.

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Offices (EPO) Opposition Division upheld patent EP 2 949 335 covering Tevas COPAXONE 40mg product in Europe.
  • The patent protects the three-times-weekly subcutaneous injection of 40 mg/mL (40mgTIW) of glatiramer acetate for the treatment of certain forms of multiple sclerosis.
  • Richard Daniell, Executive Vice President Teva Europe noted: We are pleased that the EPO agreed with Tevas stance on the patent for COPAXONE 40mg.
  • Teva will continue to robustly defend the validity of the intellectual property portfolio protecting COPAXONE 40mg.

2019 Drug Insight: Copaxone - Product Details, Sales Assessment, Patent Details, Market Competition, Emerging Therapies - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2019
Health, Clinical trials, Pharmaceutical, Glatiramer acetate

Copaxone Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.

Key Points: 
  • Copaxone Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report covers the Global Market Assessment of the Copaxone covering the historical global sales and also provides the Copaxone sales estimation during the forecasted period (2019-2021).
  • The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country.
  • In addition to this, the report also provides the SWOT analysis for Copaxone and emerging therapies in this space.

Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate Court

Retrieved on: 
Friday, October 12, 2018
Glatiramer acetate, Economy, Teva Pharmaceutical Industries, Mylan, United States patent law, Inter partes review, Medicine, MYL

(NASDAQ: MYL) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the District of Delaware's decision that Teva's Copaxone 40 mg/mL dosing patents are invalid as obvious.

Key Points: 
  • (NASDAQ: MYL) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the District of Delaware's decision that Teva's Copaxone 40 mg/mL dosing patents are invalid as obvious.
  • The Federal Circuit also affirmed today the final written decisions issued by the Patent Trial and Appeal Board in three inter partes reviews filed by Mylan related to the same patents.
  • These were the last remaining patent infringement cases Mylan was defending in the U.S. relating to Glatiramer Acetate Injection 40mg/mL.
  • Approximately 400,000 individuals in the U.S. have MS and relapsing MS accounts for 85% of initial MS diagnoses.

Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting

Retrieved on: 
Saturday, April 21, 2018
Mylan, Glatiramer acetate, American Academy of Neurology, Medicine, MYL, Aan, Health care, Clinical medicine

HERTFORDSHIRE, England, and PITTSBURGH, April 21, 2018 /PRNewswire/ --Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced three scientific abstracts from the Glatiramer Acetate development program will be presented at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, April 21-27.

Key Points: 
  • HERTFORDSHIRE, England, and PITTSBURGH, April 21, 2018 /PRNewswire/ --Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced three scientific abstracts from the Glatiramer Acetate development program will be presented at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, April 21-27.
  • Mylan's Head of Morgantown Research & Development Patrick Vallano commented, "We are excited to present at this year's American Academy of Neurology annual meeting Mylan's rigorous equivalence data that demonstrated sameness between Mylan's Glatiramer Acetate and Copaxone.
  • We believe a world-renowned venue like AAN's annual meeting is the perfect opportunity for Mylan to showcase and discuss the strong science behind our Glatiramer Acetate."
  • Mylan's data will be presented during the following poster sessions at the meeting and later available in "Neurology," the official journal of AAN.